Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country
Phase 1
Study type
102 / 777 trials
PostedSponsorStudyPhaseStatus
18 Nov 2026CASI pharmaceuticals, Inc.ChinaA Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaPhase 2Not Yet Recruiting18 Nov 2026Immuneering CorporationPhase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.Phase 2Not Yet Recruiting18 Nov 2026South Rampart Pharma, Inc.United StatesA Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar ExtractionPhase 2Not Yet Recruiting17 Nov 2026AstraZenecaUnited States, Argentina, AustraliaA Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCPhase 2Not Yet Recruiting17 Nov 2026GenAns Biotechnology Co., LtdChinaGA001 Injection in Retinitis PigmentosaPhase 2Not Yet Recruiting17 Nov 2026Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.ChinaA Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)Phase 2Not Yet Recruiting17 Nov 2026NS Pharma, Inc.United States, Australia, CanadaA Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular DystrophyPhase 2Enrolling By Invitation17 Nov 2026Sinfatin S.LSpainStudy of the Effects of Rimonabant on Functional Recovery in Subacute Stroke PatientsPhase 2Not Yet Recruiting16 Nov 2026Beijing Konruns Pharmaceutical Co., Ltd.KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerPhase 2Not Yet Recruiting16 Nov 2026BiogenA Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years OldPhase 2Not Yet Recruiting16 Nov 2026CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.ChinaSYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .Phase 2Recruiting16 Nov 2026Maxona Pharmaceuticals, Inc.United StatesA Study to Evaluate the Safety and Pain Relief of MAX-001 After Surgical Removal of Wisdom TeethPhase 2Not Yet Recruiting16 Nov 2026Nanjing Immunophage Biotech Co., LtdChinaA Study of IPG11406 Tablets in Participants With Lupus NephritisPhase 2Not Yet Recruiting16 Nov 2026Telios Pharma, Inc.United StatesTL-925 for the Treatment of Allergic ConjunctivitisPhase 2Not Yet Recruiting13 Nov 2026Aclaris Therapeutics, Inc.United StatesStudy of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical TherapiesPhase 2Recruiting13 Nov 2026Eli Lilly and CompanyUnited StatesA Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerPhase 2Not Yet Recruiting13 Nov 2026GC Biopharma CorpSouth KoreaPhase 2 Study of GC4006A in Healthy AdultsPhase 2Enrolling By Invitation12 Nov 2026AbbVieA Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe PsoriasisPhase 2Not Yet Recruiting12 Nov 2026Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.ChinaClinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide AnaloguesPhase 2Not Yet Recruiting12 Nov 2026CSPC-NBP Pharmaceutical Co., Ltd.ChinaA Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisPhase 2Not Yet Recruiting12 Nov 2026Gedeon Richter Plc.United StatesSafety, Tolerability and Efficacy of RGH-202 in Social Anxiety Disorder (STAGE)Phase 2Not Yet Recruiting12 Nov 2026Institut de Recherches Internationales Servier (I.R.I.S.)A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X SyndromePhase 2Not Yet Recruiting12 Nov 2026Oruka Therapeutics, Inc.United States, CanadaAn Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque PsoriasisPhase 2Enrolling By Invitation12 Nov 2026Otsuka Pharmaceutical Development & Commercialization, Inc.VIS954 for Treating Inflammatory Skin ProblemsPhase 2Not Yet Recruiting12 Nov 2026Regeneron PharmaceuticalsStudy to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)Phase 2Not Yet Recruiting12 Nov 2026Shattuck Labs, Inc.A Study of SL-325 in Participants With Hidradenitis SuppurativaPhase 2Not Yet Recruiting12 Nov 2026Sinfatin S.LSpainRimonabant for Cognitive Impairment in People With Post-COVID-19 SyndromePhase 2Not Yet Recruiting10 Nov 2026Beijing Supreme Life Pharmaceutical Technology Co., Ltd.ChinaFuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin TherapyPhase 2Not Yet Recruiting10 Nov 2026Eli Lilly and CompanyUnited States, Bulgaria, HungaryA Study of Brenipatide in Participants With Major Depressive DisorderPhase 2Not Yet Recruiting10 Nov 2026Genrix (Shanghai) Biopharmaceutical Co., Ltd.A Clinical Trial of Multiple Doses of GR2301 Injection in Participants With Vitiligo.Phase 2Not Yet Recruiting10 Nov 2026Hangzhou Sciwind Biosciences Co., Ltd.ChinaA Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityPhase 2Not Yet Recruiting10 Nov 2026Qilu Pharmaceutical Co., Ltd.A Phase II Clinical Trial to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients With Uncontrolled Hypertension Who Are Receiving One or More Background Drug TreatmentsPhase 2Not Yet Recruiting10 Nov 2026Resurge Therapeutics Inc.RELEASE Ph2 RT-310 BPH StudyPhase 2Not Yet Recruiting10 Nov 2026SATO Pharmaceutical Co., Ltd.United StatesSafety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual OnychomycosisPhase 2Not Yet Recruiting10 Nov 2026Shenzhen NewDEL Biotech, Co., LtdChinaA Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary FibrosisPhase 2Enrolling By Invitation9 Nov 2026Boehringer IngelheimUnited States, Belgium, FinlandA Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentPhase 2Not Yet Recruiting9 Nov 2026Pharmosa Biopharm Inc.Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital UlcersPhase 2Not Yet Recruiting6 Nov 2026Eli Lilly and CompanyUnited States, Hungary, ItalyA Study of Bimagrumab in Participants With HFpEFPhase 2Not Yet Recruiting6 Nov 2026Epirium Bio Inc.MF-300 for Treatment of Age-Related SarcopeniaPhase 2Not Yet Recruiting6 Nov 2026Guangdong Hengrui Pharmaceutical Co., LtdChinaA Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar PustulosisPhase 2Not Yet Recruiting6 Nov 2026Hexin (Suzhou) Pharmaceutical Technology Co., LtdChinaA Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT ImagingPhase 2Recruiting6 Nov 2026Novartis PharmaceuticalsExtension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)Phase 2Not Yet Recruiting6 Nov 2026Shenzhen Salubris Pharmaceuticals Co., Ltd.ChinaA Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes MellitusPhase 2Not Yet Recruiting6 Nov 2026United TherapeuticsUnited StatesStudy of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)Phase 2Not Yet Recruiting5 Nov 2026Beijing Supreme Life Pharmaceutical Technology Co., Ltd.ChinaFuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle InterventionPhase 2Not Yet Recruiting5 Nov 2026BrightGene Bio-Medical Technology Co., Ltd.ChinaA Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without DiabetesPhase 2Not Yet Recruiting5 Nov 2026Somnum Pharma Inc.United StatesA Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic InsomniaPhase 2Not Yet Recruiting5 Nov 2026Suzhou HepaThera Biotech Co., Ltd.A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB)Phase 2Not Yet Recruiting4 Nov 2026GlaxoSmithKlineUnited States, United KingdomA Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Phase 2Recruiting4 Nov 2026InnovStone Therapeutics LimitedChinaSYH2072 Tablets in Participants With Primary AldosteronismPhase 2Not Yet Recruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.